Insight Into Designing of Renin Inhibitors

Posted: 19 Feb 2020

See all articles by Ramya K

Ramya K

Oxbridge College of Pharmacy; Annamalai University - Department of Pharmacy

Suresh R

Annamalai University - Department of Pharmacy

Kumar HY

JSS Academy of Higher Education and Research - Department of Pharmaceutical Chemistry

Sridhara Murthy NB

Oxbridge College of Pharmacy

Date Written: January 30, 2020

Abstract

Hypertension is a diverse illness interlinked with cerebral, cardiovascular (CVS) and renal abnormalities. Presently, the malady is being treated by focusing on Renin-angiotensin system (RAS), voltage-gated calcium channels, peripheral vasodilators, renal and sympathetic nervous systems. Cardiovascular and renal abnormalities are associated with the overactivation of RAAS, which can be constrained by angiotensin-converting enzyme inhibitors (ACEIs), angiotensin II (Ang-II)-AT1 receptor blockers (ARBs) and renin inhibitors. The latter is a new player in the old system. The renin catalyzes the conversion of angiotensinogen to Angiotensin I (Ang-I). This can be overcome by inhibiting renin, a preliminary step, eventually hinders the occurrence of the cascade of events in the RAAS. Various peptidomimetics, the first-generation renin inhibitors developed six decades ago have limited drug-like properties as they suffered from poor intestinal absorption, high liver first-pass metabolism and low oral bioavailability. The development of chemically diverse molecules from peptides to nonpeptides expanded the horizon to achieving direct renin inhibition. Aliskiren, a blockbuster drug that emerged as a clinical candidate and got approved by the US FDA in 2007 was developed by molecular modeling studies. Aliskiren indicated superior to average efficacy and with minor adverse effects relative to other RAS inhibitors. However, its therapeutic use is limited by poor oral bioavailability of less than 2% that is similar to first-generation peptidic compounds. Thus, discovery of novel renin inhibitors with improved efficacy and ADME properties are required. Here we describe our virtual screening approach for the identification of novel renin inhibitors.

We have performed molecular dynamics simulation studies to identify key interacting features of aliskiren along with water dynamics in the active sites. Identified features were utilized to perform virtual screen against external library. Hits are shortlisted based on interaction pattern and predicted bioavailability. Furthermore, these hits will be considered for synthesis and screened against renin enzyme inhibition and lowering of blood pressure in hypertensive animal models.

Keywords: Aliskiren, Docking, Hypertension, Renin, Virtual screening

Suggested Citation

K, Ramya and R, Suresh and HY, Kumar and NB, Sridhara Murthy, Insight Into Designing of Renin Inhibitors (January 30, 2020). Proceedings of International Conference on Drug Discovery (ICDD) 2020, Available at SSRN: https://ssrn.com/abstract=3528050

Ramya K (Contact Author)

Oxbridge College of Pharmacy ( email )

No.7,8,&9
Herohalli cross
Bengaluru, KARNATAKA 560091
India

Annamalai University - Department of Pharmacy ( email )

Annamalainagar
Chidambaram, Tamil Nadu 608002
India

Suresh R

Annamalai University - Department of Pharmacy

Annamalainagar
Chidambaram, Tamil Nadu 608002
India

Kumar HY

JSS Academy of Higher Education and Research - Department of Pharmaceutical Chemistry

Mysuru
India

Sridhara Murthy NB

Oxbridge College of Pharmacy

No.7,8,&9
Herohalli cross
Bengaluru, KARNATAKA 560091
India

Here is the Coronavirus
related research on SSRN

Paper statistics

Abstract Views
82
PlumX Metrics